The potential of integrated nurse-led models to improve care for people with functional gastrointestinal disorders: A systematic review by Linedale, E.C. et al.
ACCEPTED VERSION 
 
Ecushla C. Linedale, Antonina Mikocka-Walus, Peter R. Gibson, Jane M. Andrews 
The potential of integrated nurse-led models to improve care for people with 
functional gastrointestinal disorders: A systematic review 
Gastroenterology Nursing, 2020; 43(1):53-64 
 
 
Copyright © 2020 Society of Gastroenterology Nurses and Associates. 
This is a non-final version of an article published in final form in Gastroenterology 
Nursing, 2020; 43(1):53-64 































23 March 2021 
 FGID Models of Care I 
Abstract 
Functional gastrointestinal disorders (FGID) such as irritable bowel syndrome (IBS) and 
functional dyspepsia (FD) are extremely common, debilitating and costly. Although 
diagnostic guidelines and effective management options exist, management is sub-optimal, 
with long waiting lists, delayed diagnosis and poor patient outcomes. The aim of this 
systematic review was to explore and evaluate evidence for existing models of care for 
functional gastrointestinal disorders. 38 studies pertaining to the diagnosis or management of 
FGIDs were found, however only 6 investigated a full model of care. Five studies assessed a 
nurse-led model and one a structured gastroenterologist consultation. Nurse-led models were 
cheaper to current treatments, and resulted in symptomatic improvement, high patient 
satisfaction, reduced healthcare usage, and improved psychosocial functioning and quality of 
life, whilst standard gastroenterological care did not improve pain or quality of life. There is 
minimal research trialling integrated models of care for the diagnosis and management of 
functional gastrointestinal disorders.  This represents a lost opportunity for timely, effective, 
healthcare provision to a large patient group. Although low in quality, preliminary data 
suggest that integrated nurse-led models of care are economically viable and may facilitate 
timely diagnosis and management, and improve patient outcomes. Further, studies to robustly 
evaluate the efficacy, safety and acceptability of such models are needed. 






Functional gastrointestinal disorders (FGIDs) are common (Chang, Lu, & Chen, 2010; 
Mountifield, 2010), chronic and complex, with biopsychosocial triggers, shifting 
symptomatology over time (Halder et al., 2007) and the frequent presence of other 
unexplained, somatic complaints (Spiegel, Kanwal, Naliboff, & Mayer, 2005).  The most 
common FGIDs are irritable bowel syndrome (IBS) which affects approximately 10% of 
the population globally (Hulisz, 2004; Talley, 2008a) and functional dyspepsia (FD) with a 
prevalence of 15% worldwide (El-Serag & Talley, 2004; Talley, 2008a).  Symptoms of 
FGID significantly impair daily life, lead to high healthcare use and costs (Ålander, 
Svärdsudd, & Agréus, 2008; Kodner & Spreeuwenberg, 2002; Levy et al., 2001b; 
Longstreth et al., 2003; Talley, Gabriel, Harmsen, Zinsmeister, & Evans, 1995) overuse of 
investigations (E. C. Linedale, Chur-Hansen, Mikocka-Walus, Gibson, & Andrews, 2016b) 
and high levels of absenteeism and presenteeism (Talley, 2008b). Although FGIDs are 
common and significantly impact both the patient and community, they are poorly handled 
in the healthcare system creating frustration in patients and doctors alike (Knott, Holtmann, 
Turnbull, & Andrews, 2009).  
 
Recent developments of reliable, accepted diagnostic criteria (Lacy et al., 2016; Stanghellini 
et al., 2016) and effective evidence-based management options for FGIDs (Enck, Junne, 
Klosterhalfen, Zipfel, & Martens, 2010; Peters, Muir, & Gibson, 2015) do not appear to have 
been incorporated into current routine practice. Many primary healthcare providers lack 
confidence and continue to refer for specialist input (E. Linedale, Mikocka-Walus, Gibson, 
& Andrews, 2016; Mitchell & Drossman, 1987; Shivaji & Ford, 2014), with capacity 
restraints resulting in extraordinarily long wait lists. The delay in diagnosis and 
implementation of effective management options represents a lost opportunity to improve 




symptoms, quality of life and workplace productivity, and reduce unnecessary societal 
expenditure on repeat consultation, unnecessary investigations, and ineffective treatments 
(Mearin & Lacy, 2012). 
Given the chronic nature of FGIDs and the clear interplay of biological, psychological and 
social factors in triggering symptoms (Douglas A. Drossman, 2016), an integrated model 
of care (IMoC) is needed.  Integrated models of care (IMoC) have been successfully 
established in other chronic illnesses such as diabetes (General practice management of 
type 2 diabetes – 2014–15. Melbourne: , 2014) and asthma (Department of Health, 
Western Australia. Asthma Model of Care. Perth, 2012), yet have received little attention 
in FGID.  
 
A model of care is a multidimensional concept that defines the way in which healthcare 
services are delivered (Queensland Health, 2004). There are several elements of effective 
care of FGID patients which could be addressed in an IMoC. The provision of a clear 
diagnosis and patient acceptance of this diagnosis are critical to the successful management 
of patients with FGIDs. Research has shown that both patient acceptance of functional 
diagnoses and diagnostic communication from the physician are poor (J. Collins, Farrall, 
E., Turnbull, D.A., Hetzel, D.J., Holtmann, G., and Andrews, J.M., 2009; Ilnyckyj, Graff, 
Blanchard, & Bernstein, 2003; E. C. Linedale, Chur-Hansen, Mikocka-Walus, Gibson, & 
Andrews, 2016a) .  Thus, a model of care incorporating the first point of patient contact 
with the medical system is likely to greatly improve patient outcomes and reduce costs.  
Other important elements of such a model include diagnostic criteria and the coordinated 
use of newer treatments with proven efficacy for global symptom relief, including 
cognitive behavioural therapy, gut-directed hypnotherapy and the low FODMAP diet 
(Enck et al., 2010; Peters et al., 2015).  




Although there are many recommendations as to how FGID should be diagnosed and 
managed (American College of Gastroenterology Task Force on Irritable Bowel et al., 
2009; Astegiano et al., 2008; NICE, 2016), few designs have been tested to date. To inform 
the development of an IMoC for FGIDs we undertook a systematic review of existing 
models that have been tested for FGIDs. 
 
METHODS 
Types of Studies 
The protocol for this quantitative systematic review was registered at PROSPERO 
International prospective register of systematic reviews 15/01/2016 (PROSPERO 
2016:CRD42016033146) and the search conducted in January 2016. No new publications 
were identified in Jan-Dec 2016. 
 
Inclusion criteria 
Primary studies concerning the diagnosis and management of FGID, irritable bowel 
syndrome (IBS) or functional dyspepsia (diagnosed in primary, secondary or tertiary care) 
were included.  Studies of any quantitative research design published 1995-2016 and 
reporting patient related outcomes (i.e. quality of life, symptom severity) in an adult 
population were included. Both full text and abstracts were included. 
 
Exclusion criteria 
Studies regarding patients with organic disease, or functional abdominal pain were excluded, 
as were reviews, opinion pieces, dissertations, or secondary analyses. Qualitative studies, and 
those reporting cost or health-care use alone were excluded, as were studies trialling a 
treatment.  







Databases searched were PubMed, Medline, Embase, Web of Science, Cochrane, CINAHL, 
PsychInfo the ISCRTN registry. Reference lists of all included studies were also searched, 
experts in the field were contacted to identify additional references, and authors contacted for 
further information as required.  
 
Search strategy 
The search strategy covered three main concepts: functional gastrointestinal disorders, 
models and care, as indicated in Table 1.  
 
Study selection 
A systematic review was conducted according to the 5 steps outlined by Khan, Kunz, 
Kleijnen, and Antes (2003). The framing question was ‘what models of care have been 
evaluated for functional gastrointestinal disorders’. In the first phase, titles and abstracts of 
the search results were screened by the primary researcher (EL) to assess suitability for 
inclusion.  Studies whose suitability was uncertain were also screened by the second reviewer 
(AMW) and consensus reached on inclusion.  Where uncertainty regarding inclusion or 
disagreement occurred, a third researcher (JMA) was consulted and a joint decision regarding 
selection was reached.  In the second phase, full papers deemed suitable from the initial 
search were screened by both reviewers (EL, AMW) and checked against a pre-designed 
relevance checking proforma based on the inclusion/exclusion criteria.  
 
Data extraction 




Data including author, year of publication, country of origin, design, model of care, sample 
size and characteristics, disease type (for example, FGID, irritable bowel syndrome, 
functional dyspepsia), outcomes measured and results, were extracted by the primary 
researcher (EL), using a customised extraction table. Extracted data was checked against the 
original articles by the second reviewer (AMW).  
 
Data synthesis 
Due to the limited number of available studies, and heterogeneity in study design and 
outcomes measured, we provided a narrative synthesis of the findings regarding full models 
of care (including both diagnosis and management).  Studies pertaining to components of a 
model (such as diagnosis, patient education, or management) were summarised in Figure 1, 
but not synthesised. 
 
Assessment of quality and risk of bias  
Quality assessment of the 7 included studies was conducted (Supplementary Table A) using 
the Quality Assessment Tool for Quantitative Studies (Effective Public Health Practice 
Project) (Project, 2007) as recommended by the Cochrane group ("Cochrane Handbook for 
Systematic Reviews of Interventions "). This scale allows all quantitative study designs to be 
assessed with one tool. Studies were assessed in 6 domains: selection bias, study design, 
confounders, blinding, data collection methods, withdrawal and dropouts, intervention 
integrity and analyses and scored according to the rules (Project, 2007). An overall global 
rating was given based on the number of weak domain ratings (strong=no weak ratings, 
moderate=1 weak rating, weak=2 or more weak ratings). Studies were appraised 
independently by EL and AMW, and an overall rating reached by consensus. All studies 
regardless of quality rating were included in this review due to the scarcity of research found. 







Out of the 95 full text articles identified, 57 were excluded (Figure 1) for reasons that 
included: non-primary research (n=14), treatment trial (n=10), duplicate abstract, protocol or 
secondary analysis of full-text article already included (n=15), not pertaining to FGID (n=4), 
or IMoC (n=6), assessed outcomes not in inclusion criteria (n=7), data unpublished (n=1). Of 
the 38 unique primary research studies that pertained to diagnosis or management of FGIDs 
(Figure 1), only 6 were deemed suitable for inclusion as a full IMoC, including both a 
diagnostic and management component. A summary of the studies that considered only one 
of these components of care (i.e. diagnosis OR management) is presented in Supplementary 
Table B. An overview of these studies is included, as the examined components may be 
relevant to inform the development of a full IMoC for FGID (Figure 2). A review of 
individual components is outside the scope of this review. 
 
Nature of studies 
Included studies were all low in quality (Table 2). Two studies were published in abstract 
form only, and full data were unable to be analysed (Buresi et al., 2014; Novak et al., 2014), 
and one described subjective changes in patient outcomes without reference to baseline or 
statistical analysis (Dill & Dill, 1995). One study was a randomised controlled trial 
(Bengtsson, Ulander, Borgdal, & Ohlsson, 2010), 3 observational (Dill & Dill, 1995; Ilnyckyj 
et al., 2003; Moore, Gagan, & Perry, 2014)  and 2 non-randomised controlled designs (Buresi 
et al., 2014; Novak et al., 2014).  Four studies evaluated IBS IMoCs in Sweden (Bengtsson et 
al., 2010), USA (Dill & Dill, 1995), Canada (Ilnyckyj et al., 2003) and New Zealand (Moore 
et al., 2014), and 2 studies, in abstract form only, evaluated IMoCs for functional dyspepsia 




in Canada (Buresi et al., 2014; Novak et al., 2014).  No studies presented an IMoC for FGIDs 
in general. Due to the small number, studies regarding irritable bowel syndrome and 
functional dyspepsia are not discussed separately.  Five articles assessed some form of a 
nurse-led care model (Bengtsson et al., 2010; Buresi et al., 2014; Dill & Dill, 1995; Moore et 
al., 2014; Novak et al., 2014), and one evaluated the performance of a structured 
gastroenterologist consultation (13).   
 
Summary of full models of care  
Nurse-led models 
Five studies evaluated a nurse-led model (Bengtsson et al., 2010; Buresi et al., 2014; Dill & 
Dill, 1995; Moore et al., 2014; Novak et al., 2014). These models differed in the setting, role 
and timing of nurse management. Roles included the provision of active triage and patient 
education prior to a consult with a gastroenterologist (Bengtsson et al., 2010; Novak et al., 
2014), ongoing holistic management post-diagnosis (Dill & Dill, 1995), screening and 
treatment trials prior to gastroenterologist consultation (Buresi et al., 2014) and independent 
nurse diagnosis and management (Moore et al., 2014). Full description of the models and 
findings are presented in Table 2. 
 
Four of the 5 nurse-led studies measured symptom severity and patient satisfaction.  
Symptomatic improvement was seen in all (Bengtsson et al., 2010; Dill & Dill, 1995; Moore 
et al., 2014; Novak et al., 2014).  One study reported subjective improvement following the 
intervention (no baseline comparator) (Dill & Dill, 1995), 2 compared to baseline at 3 (Moore 
et al., 2014) and 6 months (Novak et al., 2014) follow-up, and 1 compared to control group 
(mean GOS change -0.6±0.1, p<0.001) (Bengtsson et al., 2010).  Patient satisfaction was high 
(Dill & Dill, 1995; Novak et al., 2014) or improved compared to baseline (Moore et al., 




2014), with the exception of the model reported by Bengtsson et al. (2010) where the nurse’s 
role was to implement a care plan prior to consultation with a gastroenterologist. Two studies 
evaluated healthcare utilisation and showed reduced gastroenterologist visits compared with 
treatment as usual controls (Bengtsson et al., 2010), and reduced doctor visits following the 
intervention (Dill & Dill, 1995).  Psychosocial health was measured in various forms in 4 
studies with overall improvement found in all (Buresi et al., 2014; Dill & Dill, 1995; Moore 
et al., 2014) except that reported by Bengtsson et al. (2010). Studies that assessed quality of  
life (Buresi et al., 2014; Moore et al., 2014) and psychosocial functioning (Dill & Dill, 1995) 
showed improvement, but Moore et al. (2014) found no simultaneous improvement in coping 
strategies.  The cost of a nurse-led model was assessed in two studies and found to be 
significantly reduced compared to current treatments (Buresi et al., 2014; Dill & Dill, 1995).  
 
Structured gastroenterologist care 
Only 1 observational cohort study investigated the value of a structured gastroenterologist 
consultation (Ilnyckyj et al., 2003).  The consultation included establishing a positive 
diagnosis, investigations as indicated, education and reassurance, and psychological referrals 
as appropriate. Ambulatory gastroenterology visits returned to and remained at baseline 
levels for 2 years’ post-consultation.  However, other ambulatory and psychiatric healthcare 
utilisation remained unchanged.  In addition, quality of life and pain also remained 
unchanged at 1-year follow up, although a reduction in pain was seen at the 2-year mark. 
 
  





This systematic review demonstrates that, despite FGIDs being highly prevalent, there is a 
paucity of data examining IMoC for FGIDs. This represents a lost opportunity for effective 
and efficient provision of care to this large patient group, which can be ill-afforded 
considering the need for cost constraint and optimal outcomes in healthcare systems 
worldwide. While a number of studies relate to the management of FGIDs, there is minimal 
research into IMoC which incorporate both diagnosis and management. This review 
considers IBS and FD together, as they often co-occur and thus are best treated as one clinical 
group. Many patients with IBS will subsequently have FD and visa-versa. In general, our 
healthcare systems function more efficiently when related conditions affecting one large 
patient group receive a similar (but not rigidly identical) approach. The current approaches to 
the diagnosis and management for IBS and FD are very similar; namely exclude alarms, offer 
reassurance, explanation, and recommend lifestyle changes, psychological and/or dietary 
therapies and medication when needed. 
 
FGIDs are significant and growing public health problem (Talley, 2008b), with up to 40% of 
the population affected within their lifetime (2), and referrals representing up to 50% of 
gastroenterology workload (Mitchell & Drossman, 1987; Shivaji & Ford, 2014).   There is a 
high economic cost of FGIDs, with an estimated annual cost of 41 billion dollars (US) for IBS 
alone, in the UK, Japan, Australia, Sweden, Germany, France, and Canada in 2000 (Fullerton, 
1998). These costs are driven by persistent and/or unmanaged symptoms, unnecessary 
investigations, repeated healthcare visits and workplace impairment (Fortea & Prior, 2013; 
Talley, 2008a), and represent a significant opportunity for improved healthcare service 
delivery. 
 




Dill and Dill (1995) describe the first nurse-led IBS model and its effectiveness in a single 
private practice in the USA in 1995. This study provides preliminary evidence to suggest the 
economic and clinical benefit of a nurse-led IMoC. Surprisingly, further assessment of this 
model did not occur for another 25 years.  However, recent studies show benefits of 
integrated nurse-led models on symptoms, psychosocial well-being and quality of life (Buresi 
et al., 2014; Dill & Dill, 1995; Moore et al., 2014; Novak et al., 2014). In addition, nurse-led 
clinics were more cost-effective and may enable a larger volume of patients to be seen in 
specialist care. The use of a nurse to screen referrals and implement treatment trials in 
patients with no alarm features was effective, both independently of gastroenterology 
consultation (Moore et al., 2014)  and in conjunction with specialist review (Buresi et al., 
2014; Dill & Dill, 1995; Novak et al., 2014). The only ineffective nurse-led model was 
dependent upon an accurate primary care diagnosis (which was found to be lacking), giving 
further credence to the importance of including diagnosis in a model of care.  Traditional 
gastroenterological care was assessed in only 1 study and was not effective in reducing 
symptoms, or improving quality of life. However, this study was not controlled, and the 
approach to diagnosis and management was not standardised.   
 
Although these studies differed in the clinicians used and the role they played, several 
common features were apparent.  All models included a standardised diagnostic pathway, 
provided patient education and reassurance, and focussed on enabling the patient to self-
manage their condition.  The nurse-led models also provided continuing review, support and 
co-ordination of care.  
 
The overall quality of included studies is low, with most having design, sampling, or 
reporting limitations.  All studies used convenience samples of referred patients, and most 




study designs were observational or non-randomised control designs.  In addition, all studies 
assessed either functional dyspepsia or irritable bowel syndrome, not a model of care for all 
FGIDs, and the long-term effect of these models was not assessed. Despite the low quality of 
evidence, these studies do provide preliminary evidence for the potential effectiveness of 
nurse-led, integrated models of care in FGID, and further larger scale, high quality trials are 
warranted. 
 
The lack of research (and interest) in models of care for FGID to date, is most likely 
influenced by a poor understanding of the mechanism for pathogenesis in FGIDs, lack of 
diagnostic tests and uniformly effective management options, as well as differences between 
and changes within healthcare systems worldwide (Agréus, 2002; Levy et al., 2001a). 
However, with recent advances in the development of positive diagnostic criteria and 
effective global symptom management strategies, it is now possible to develop a model of 
care which can be implemented in virtually any developed country.  
 
This review specifically targeted only those studies pertaining to an integrated approach to 
the diagnosis and management of FGIDs.  The process of diagnosis is a critical component to 
the model of care. Many clinicians consider a functional diagnosis, but are reluctant to 
communicate this to the patient (Mearin & Lacy, 2012) or to document it (Harkness, Grant, 
O'Brien, Chew-Graham, & Thompson, 2013), and many patients are reluctant to accept a 
functional diagnosis (J. Collins et al., 2009).  However, a timely, clear, accurate diagnosis is 
critical in FGIDs, as it provides reassurance, alleviates patients’ concerns and helps move the 
patient from a diagnostic search to an effective management strategy [35, 42].   
 
 





Despite the shortcomings in our understanding, we do have a useful biopsychosocial model 
(implicating psychological state, increased  motor reactivity, visceral hypersensitivity, 
changes in mucosal immune/inflammatory function and altered enteric nervous system) (D. 
A. Drossman, 2006), diagnostic guidelines (NICE, 2016) and effective dietary/psychological 
treatment options (De Giorgio, Volta, & Gibson, 2016; Peters et al., 2015).  Although 
guidelines recommend a biopsychosocial approach to the management of FGIDs, little 
direction is given on how (Irritable Bowel Syndrome IBS, 2003; Lacy et al., 2016; NICE, 
2016; Quigley et al., 2016). The Rome IV criteria recommend a tiered approach to the 
management of FGIDs according to symptom severity (Lacy et al., 2016). Current 
recommendations from the National Institute for Health and Clinical Excellence (NICE) are 
that FGIDs are diagnosed in primary care based on characteristic symptoms without alarms, 
with the judicious use of investigations (Dalrymple & Bullock, 2008). Referral for 
psychological interventions are recommended if no symptom improvement after 12 months’ 
treatment with lifestyle modification and symptom based pharmacotherapy. The development 
of a standard IMoC that incorporates both a diagnostic and evidence-based management 
pathway is the next step forward in improving patient care for FGIDs. Key components of 
such a model, include the provision of a timely, clear diagnosis, patient education, 
empowerment, care co-ordination, multi-disciplinary teams, and individual care plans 
(Carter, Chalouhi, McKenna, & Richardson, 2011). 
 
Future Directions 
This review highlights the paucity of research into the development and assessment of 
integrated models of care for FGIDs. However, the preliminary evidence indicates a role for 
nurse-led models of care in FGIDs. Future studies should be large, randomised controlled 




trials, comparing standard gastroenterological care with integrated models, with both patient 
outcomes and cost evaluated.  Detailed descriptions of the content of both the diagnostic and 
management arms of the model of care are also needed to evaluate whether components of 
IMoC are evidence-based, and effective. Furthermore, evidence of the standardisation of the 
IMoC within the trial is also necessary to ensure accuracy of the findings.  
 
In conclusion, there is minimal research to date trialling models of care which incorporate a 
standardised approach to diagnosis as well as evidence-based management.  Furthermore, no 
studies have assessed FGIDs in general, but restricted to either functional dyspepsia or 
irritable bowel syndrome. Existing research on full models of care is of low quality, with 
most pertaining to nurse models of care.  However, these preliminary data suggest that 
models of care that incorporate protocol driven assessment and diagnosis, in conjunction with 
ongoing holistic care are economically viable, can be delivered by nurses, and may facilitate 
timely diagnosis and management, and improve patient outcomes. 
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